---
search:
  boost: 3
---

# Other Agents

This is a subcategory of Respiratory Agents.

## Decision Tree

- [Respiratory - Other Agents - NP Criteria - Daliresp (BvG), roflumilast](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMDJWRURRM0Y3VjFBOFlPUllQRFVSNzhEWiQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred | Generic Name | Quantity | Time (Days) |
| :-------- | :----------- | :------: | :---------: |
|           |              |          |             |

### Non-Preferred

| Non-Preferred              | Generic Name | Quantity | Time (Days) |
| :------------------------- | :----------- | :------: | :---------: |
| Roflumilast                |              |          |             |

## Authorizations

**Length of Authorizations**: Initial: 90 days; Subsequent: 180 days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response to at least **90 days** with at least **one preferred** long-acting beta agonist **AND one preferred** long-acting muscarinic antagonist-containing inhalers
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Roflumilast (Daliresp)

Additional Roflumilast (Daliresp) Criteria

- Must be used in addition to a long-acting beta agonist AND a long-acting muscarinic antagonist-containing inhalers 

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment, adherence to maintenance inhaler per pharmacy claims, and ongoing safety monitoring

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=99&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"} 

[Criteria](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20criteria%20effective%2001.01.2024.pdf#page=101){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20effective%2001.01.2024.pdf#page=32){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/Quantity%20Limits.pdf){ :target="_blank" rel="noopener"}
